- Back-translation from clinic to animal test: efficacy of current and past antipsychotics in the attenuation of d-amphetamine induced hyperlocomotion in Wistar-Han rats
R. Kabir1,2, D. Schnell3, J. Freudenreich2, A. Ceci2. 1School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 2CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riá, Germany, 3Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riá, Germany,
- Beyond the hype, How AI is disrupting drug discovery and development
B. Balali-mood. Mood Biopharma Consulting, London, United Kingdom,
- Characterising the catalytic mechanism of a Methyltransferase for use in oncology drug discovery
A. Eddershaw1, A. Argyrou1, C. Stubbs2, P. Clarkson1, K. Syson1. 1Discovery Biology, AstraZeneca, Cambridge, United Kingdom, 2Structure and Biophysics, AstraZeneca, Cambridge, United Kingdom,
- High-throughput screening for IRF4 inhibitors
S. Stevens, J. Lopez Fernandez. Newcastle University, Newcastle upon Tyne, United Kingdom,
- Methods for collection and quality assessment of pharmacokinetic data
R. Porter, L. J. Camidge. Lhasa Limited, Leeds, United Kingdom,
- Molecular availability and accessibility - measuring and understanding cellular drug concentrations
C. Messenger1, L. Gordon1, M. Hann2. 1Screening, Profiling and Mechanistic Biology, GSK, Stevenage, United Kingdom, 2R&D Platform Technology & Science, GSK, Stevenage, United Kingdom,
- Probe Miner: objective assessment of chemical probes to de-risk chemical biology and follow-up drug discovery
A. A. Antolin, J. E. Tym, I. Collins, P. Workman, B. Al-Lazikani. Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom,
- Synthesis and evaluation of novel non-peptide agonists of NPR-C
D. Conole1, S. H. Myers1, D. L. Selwood1, A. J. Hobbs2, C. P‚rez-Ternero2. 1Wolfson Institute for Biomedical Research, University College London, London, United Kingdom, 2William Harvey Research Institute, Heart Centre, Barts & The London School of Medicine, Queen Mary University of London, London, United Kingdom,
- The use of surrogate markers in european medicines agency fast track approval pathways-are they validated
C. S. Schuster Bruce1, P. McGettigan1, P. Brhlikova2. 1William Harvey Research Institute, London, United Kingdom, 2Newcastle University,, Newcastle, United Kingdom,
- Translational understanding of the cardiovascular risk due to alpha2A-adrenoceptor antagonism
L. Roberts1, C. W. Scott2, A. Harmer1. 1Discovery Safety, AstraZeneca, Cambridge, United Kingdom, 2Discovery Safety, AstraZeneca, Waltham,